Cargando…

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332

Detalles Bibliográficos
Autores principales:	Zhao, Yao, Fang, Chao, Zhang, Qi, Zhang, Ruxue, Zhao, Xiangbo, Duan, Yinkai, Wang, Haofeng, Zhu, Yan, Feng, Lu, Zhao, Jinyi, Shao, Maolin, Yang, Xiuna, Zhang, Leike, Peng, Chao, Yang, Kailin, Ma, Dawei, Rao, Zihe, Yang, Haitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Higher Education Press 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533666/ https://www.ncbi.nlm.nih.gov/pubmed/34687004 http://dx.doi.org/10.1007/s13238-021-00883-2

Ejemplares similares

Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332
por: Li, Jian, et al.
Publicado: (2022)

Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332
por: Zhou, Yanru, et al.
Publicado: (2023)

Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2
por: Zhao, Yao, et al.
Publicado: (2022)

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
por: Macchiagodena, Marina, et al.
Publicado: (2022)

The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2
por: Jin, Zhenming, et al.
Publicado: (2021)

Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332
por: Pavan, Matteo, et al.
Publicado: (2021)

Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
por: Lin, Mengmeng, et al.
Publicado: (2023)

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
por: Joyce, Ryan P., et al.
Publicado: (2022)

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)
por: Shekhar, Chandra, et al.
Publicado: (2022)

Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
por: Amporndanai, Kangsa, et al.
Publicado: (2021)

Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
por: Yang, Haitao, et al.
Publicado: (2005)

Crystal Structure of Human Coronavirus NL63 Main Protease in Complex With an Inhibitor
por: Yang, Kailin, et al.
Publicado: (2015)

Correction: Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
por: Yang, Haitao, et al.
Publicado: (2005)

Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations
por: Ahmad, Bilal, et al.
Publicado: (2021)

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
por: Dai, Wenhao, et al.
Publicado: (2020)

High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors
por: Zang, Yi, et al.
Publicado: (2022)

Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT
por: Alvarado, Ysaias José, et al.
Publicado: (2022)

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
por: Heskin, Joseph, et al.
Publicado: (2022)

Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814
por: Li, Jian, et al.
Publicado: (2022)

Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19
por: Cui, Wen, et al.
Publicado: (2020)

Optimization of the expression of the main protease from SARS-CoV-2
por: Rong, Yi, et al.
Publicado: (2023)

Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design
por: Wang, Fenghua, et al.
Publicado: (2016)

Crystal structures of main protease (M(pro)) mutants of SARS-CoV-2 variants bound to PF-07304814
por: Jiang, Haihai, et al.
Publicado: (2023)

Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 M(pro)
por: Ngo, Son Tung, et al.
Publicado: (2022)

Recent progress in the discovery of inhibitors targeting coronavirus proteases
por: Wang, Haofeng, et al.
Publicado: (2016)

Crystallization and preliminary crystallographic study of Feline infectious peritonitis virus main protease in complex with an inhibitor
por: Wang, Jinshan, et al.
Publicado: (2014)

Crystallization and preliminary crystallographic study of Porcine epidemic diarrhea virus main protease in complex with an inhibitor
por: Tan, Yusheng, et al.
Publicado: (2014)

The crystal structure of main protease from mouse hepatitis virus A59 in complex with an inhibitor
por: Cui, Wen, et al.
Publicado: (2019)

PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients
por: Hau, Raymond K., et al.
Publicado: (2022)

Crystallization and preliminary crystallographic study of human coronavirus NL63 main protease in complex with an inhibitor
por: Wang, Fenghua, et al.
Publicado: (2014)

Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M(pro) inhibitor in animal models
por: Catlin, N.R., et al.
Publicado: (2022)

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
por: Liu, Jian, et al.
Publicado: (2021)

Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease
por: Ngo, Chau, et al.
Publicado: (2023)

High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors
por: Zhao, Yao, et al.
Publicado: (2021)

Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design
por: Yu, Wei, et al.
Publicado: (2021)

C-terminal domain of SARS-CoV main protease can form a 3D domain-swapped dimer
por: Zhong, Nan, et al.
Publicado: (2009)

The Structure of the Porcine Deltacoronavirus Main Protease Reveals a Conserved Target for the Design of Antivirals
por: Wang, Fenghua, et al.
Publicado: (2022)

Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry
por: Wang, Haofeng, et al.
Publicado: (2023)

In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2
por: Shang, Weijuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g4viaokg5qa0eqqrfb3edmcnjm